Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
The latest announcement is out from Autonomix Medical, Inc. ( (AMIX) ).
On October 30, 2025, Autonomix Medical, Inc. held its annual meeting of stockholders, where a quorum was achieved with 48% of shares voting. During the meeting, all director nominees were elected, and several proposals were approved, including the appointment of Forvis Mazars, LLP as the independent accounting firm, an amendment for a potential reverse stock split, the amended 2023 Equity Incentive Plan, and a stock issuance in compliance with Nasdaq rules.
The most recent analyst rating on (AMIX) stock is a Buy with a $5.00 price target. To see the full list of analyst forecasts on Autonomix Medical, Inc. stock, see the AMIX Stock Forecast page.
Spark’s Take on AMIX Stock
According to Spark, TipRanks’ AI Analyst, AMIX is a Underperform.
Autonomix Medical, Inc. struggles with severe financial performance issues due to zero revenue and negative cash flow, despite low debt levels. Technical analysis suggests some short-term momentum, but a longer-term downtrend persists. Valuation is significantly impacted by negative earnings and no dividend yield. Positive trial outcomes present a potential opportunity but are insufficient to offset the substantial financial challenges.
To see Spark’s full report on AMIX stock, click here.
More about Autonomix Medical, Inc.
Average Trading Volume: 404,313
Technical Sentiment Signal: Sell
Current Market Cap: $6.38M
See more data about AMIX stock on TipRanks’ Stock Analysis page.